Clinical Trial Update: Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI [Phase 2]

View source ↗

Summary

Phase II study of SY-3505 in ALK-positive non-small cell lung cancer patients after failure of prior second-generation ALK inhibitors is ongoing with an unknown…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SY-3505

Snippet

Sponsor: Shouyao Holdings (Beijing) Co. LTD | Conditions: Non-small-cell Lung Carcinoma | Phase 2 | Status: UNKNOWN